Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 6/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518167 | 0.92 | KCNA5 (0.40) | GAAKCNA5KCNJ5KCNJ3CNR1 | |
| SCHEMBL3516991 | 0.87 | CNR1 (0.42) | GAAKCNA5KCNJ5KCNJ3CNR1 | |
| SCHEMBL3519760 | 0.83 | SCN9A (0.37) | MEN1KMT2AGAACNR1PKM | |
| SCHEMBL3515695 | 0.82 | PKM (0.45) | MEN1KMT2AGAAMAPTTP53 | |
| SCHEMBL3519277 | 0.82 | CNR1 (0.42) | KMT2AGAAKCNA5KCNJ5KCNJ3 | |
| SCHEMBL3515688 | 0.81 | EP300 (0.37) | MEN1KMT2AGAAKCNA5KCNJ5 | |
| SCHEMBL3521032 | 0.78 | CNR1 (0.46) | MEN1KMT2AGAAKCNA5KCNJ5 | |
| SCHEMBL9893296 | 0.78 | GAA (0.46) | MEN1KMT2AGAAKCNA5KCNJ5 | |
| SCHEMBL9893251 | 0.78 | KCNA5 (0.51) | KCNA5KCNJ5KCNJ3 | |
| SCHEMBL3516032 | 0.74 | GAA (0.41) | MEN1KMT2AGAAKCNA5KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940889-B2 | Process for producing benzo [b] [1,4] diazepine-2,4-dione compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8796447-B2 | Process for producing benzo[B][1,4]diazepine-2,4-dione compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20140194621-A1 | PROCESS FOR PRODUCING BENZO [B] [1,4] DIAZEPINE-2, 4-DIONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| EP-2468733-A1 | PROCESS FOR PRODUCING BENZO[B][1,4]DIAZEPINE-2,4-DIONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120149899-A1 | PROCESS FOR PRODUCING BENZO[B][1,4]DIAZEPINE-2,4-DIONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149899-A1 | PROCESS FOR PRODUCING BENZO[B][1,4]DIAZEPINE-2,4-DIONE COMPOUND | KCNH1, KCNB2, KCNJ2 | MEN1 768/4885KMT2A 1613/4885GAA 3852/4885 |
| US-20140194621-A1 | PROCESS FOR PRODUCING BENZO [B] [1,4] DIAZEPINE-2, 4-DIONE COMPOUND | KCNH1, KCNB2, KCNB1 | MEN1 657/4885KMT2A 1399/4885GAA 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.